Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγ ligand and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. Here we report synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives as an alternate remedy for insulin resistance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207384PMC
http://dx.doi.org/10.1155/2013/201580DOI Listing

Publication Analysis

Top Keywords

synthesis n-6-4-piperazin-1-ylphenoxypyridin-3-ylbenzenesulfonamide
8
n-6-4-piperazin-1-ylphenoxypyridin-3-ylbenzenesulfonamide derivatives
8
metabolic syndrome
8
type diabetes
8
diabetes mellitus
8
insulin resistance
8
derivatives treatment
4
treatment metabolic
4
syndrome metabolic
4
syndrome prevalent
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!